DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
About two-thirds of people without diabetes stop within a year — but only around a third of them actually restart, far fewer than intend to. The industry treats GLP‑1s as permanent therapy; in practice the pattern is cyclical, and the return trip is where people fall down. Here is how it actually unfolds.
The first month sets expectations. Most patients experience appetite reduction within days, GI side effects within the first week, and the first real weight loss by week 3-4.
Dose escalation typically every 4 weeks. Each step usually triggers a wave of nausea that fades within 7-14 days. This is the most attrition-prone phase.
Once at maintenance dose, weight loss continues at a slower, steadier pace. This is the most-comfortable phase clinically but the highest-cost phase financially.
Most users plateau between months 8 and 12. The body adapts to lower caloric intake; weight stabilizes even at maintenance dose. Distinguishing under-dosed vs. genuinely plateaued is the key question.
Roughly two-thirds of people without diabetes stop within a year (about 65%, though estimates run from 37% to 81% depending on who is counting). Reasons: cost, side effects, the "graduation" assumption, supply gaps. Weight regain is the rule, not the exception, without a maintenance plan.
Far more people intend to restart than actually do — only about a third (36%) of those without diabetes restart within a year. If you are planning a break, plan the return now, because the evidence says the return is where people fall down. Titration is often shorter the second time, but the maintenance dose is the same.
Editorial summaries, not medical advice. Each stage references the relevant pivotal trial data and real-world evidence.